Ionis Pharmaceuticals — Nov 6, 2024 release

In September 2024, Ionis issued 11.5 million shares of its common stock at a public offering price of $43.50 per share that generated gross proceeds of $500 million, before deducting underwriting discounts and commissions and other offering expenses payable by Ionis. The Company plans to continue deploying its capital resources toward growth opportunities, and projects to end 2024 with $2.2 billion in cash, cash equivalents and short-term investments. Ionis’ working capital also increased over the same period primarily due to the Company’s higher cash and short-term investments balance. As a result of Ionis’ advancing pipeline that has delivered several positive data readouts, Ionis expects to make increased investments in the years ahead with the goal to realize the value of these opportunities, with a focus on its wholly owned late-stage and next wave of innovative medicines. Webcast Management will host a conference call and webcast to discuss Ionis’ third quarter 2024 results at 11:30 a.m. Eastern time on Wednesday, November 6, 2024. Interested parties may access the webcast here . A webcast replay will be available for a limited time at the same address. To access the Company’s third quarter 2024 earnings slides click here . For more information about SPINRAZA and QALSODY, visit https://www.spinraza.com/ and https://www.qalsody.com/ , respectively. QALSODY is approved under accelerated approval based on reduction in plasma neurofilament light chain (NfL) observed in patients treated with QALSODY. Continued approval may be contingent upon verific